Jefferies Financial Group Inc. Buys Shares of 50,000 BioAge Labs, Inc. $BIOA

Jefferies Financial Group Inc. bought a new stake in BioAge Labs, Inc. (NASDAQ:BIOA) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 50,000 shares of the company’s stock, valued at approximately $206,000. Jefferies Financial Group Inc. owned approximately 0.14% of BioAge Labs as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Geode Capital Management LLC raised its position in BioAge Labs by 60.8% during the second quarter. Geode Capital Management LLC now owns 453,455 shares of the company’s stock valued at $1,873,000 after buying an additional 171,426 shares during the period. Intech Investment Management LLC purchased a new stake in shares of BioAge Labs in the second quarter worth approximately $60,000. Public Employees Retirement System of Ohio purchased a new stake in shares of BioAge Labs in the second quarter worth approximately $57,000. Finally, Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of BioAge Labs during the second quarter worth approximately $27,000.

Analysts Set New Price Targets

A number of research firms have issued reports on BIOA. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research report on Thursday, October 30th. Citigroup lifted their price objective on BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Wednesday, October 29th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and a consensus target price of $15.00.

BioAge Labs Price Performance

BIOA stock opened at $9.30 on Friday. The business has a 50 day simple moving average of $6.89. BioAge Labs, Inc. has a 12 month low of $2.88 and a 12 month high of $20.37. The company has a market capitalization of $333.41 million, a P/E ratio of -6.12 and a beta of 1.98.

BioAge Labs (NASDAQ:BIOA) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.67) by $0.11. The business had revenue of $2.05 million during the quarter.

BioAge Labs Company Profile

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging.